Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aurillion names new vice president of sales and marketing
In this role, Mr Moreno is responsible for developing and implementing strategic initiatives to grow the company’s business throughout the Americas, Europe and Asia. He is based in
In this role, Mr Moreno is responsible for developing and implementing strategic initiatives to grow the company’s business throughout the Americas, Europe and Asia. He is based in
As one of four suppliers of cryoprecipitate in China, China Biologic has been engaged in a contract to supply cryoprecipitate to Green Cross China for use in the
Memory Pharmaceuticals is currently conducting a Phase II trial of R3487/MEM 3454 in cognitive impairment associated with schizophrenia (CIAS), and the companies have agreed to expand the study
Depomed’s Phase III registration program for Gabapentin GR in menopausal hot flashes includes two randomized, double-blind, placebo-controlled studies of approximately 540 patients per study. In each study, patients
Under the terms of the agreement, Biovail has paid $100 million to acquire 100% of Prestwick Pharmaceuticals and related license rights. Beyond Xenazine, the acquisition also provides Biovail
The Phase IIb study is a randomized, double-blind, placebo-controlled study that is designed to assess the safety and efficacy of Xiaflex, when administered two times a week every
Dr Soni joins Amarin from Pfizer where he held a number of leadership roles in Pfizer global R&D in both experimental medicine and late stage development. Amarin has
The CINtec cytology kit is an immuno-cytochemistry assay for the qualitative detection of the p16INK4a antigen on cervical cytology preparations. It is intended to be used as an
The agreements, which provide Signum with combined upfront license fees and investment funds in the seven figures, give Rohto a non-exclusive right to develop and sell products in
Merck’s decision triggers an additional $9 million payment to SurModics from Merck. Merck’s decision to discontinue the collaboration was made following a strategic review of its business and